Clinical Trials Browser

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03634241 2026-04-16

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Phase 2 Completed

45 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05107219 2026-04-07

GCC Agonist Signal in the Small Intestine

Phase 1 Completed

43 enrolled

Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux, Gastrointestinal Neoplasms

Clinical Trials

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

LIN-BRiCK

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

GCC Agonist Signal in the Small Intestine

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

iSITE

Lung Cancer Risk Assessment and Etiology

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer

Prostate Resection After Microwave Ablation (PRAMA)

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Community Awareness, Resources and Education (CARE II) Project: Project 1

CAR-LAM

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer